Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer
Xiaojing Zhang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Contribution: Conceptualization (equal), Data curation (equal), Formal analysis (lead), Funding acquisition (equal), Methodology (lead), Software (lead), Writing - original draft (lead)
Search for more papers by this authorSutian Jiang
Department of Pathology, Lishui People's Hospital, Lishui, Zhejiang, China
Contribution: Conceptualization (equal), Data curation (equal), Methodology (equal), Software (equal), Writing - original draft (equal)
Search for more papers by this authorHang Yin
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Contribution: Formal analysis (equal), Investigation (equal), Methodology (equal)
Search for more papers by this authorHui Zhang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Contribution: Methodology (equal), Resources (equal), Software (equal)
Search for more papers by this authorLei Yang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Contribution: Formal analysis (equal), Software (equal), Software (equal), Validation (equal), Validation (equal)
Search for more papers by this authorPingping Sun
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Contribution: Conceptualization (equal), Investigation (equal)
Search for more papers by this authorXiaoling Kuai
Department of Gastroenterology, Nantong University Affiliated Hospital, Nantong, Jiangsu, China
Contribution: Funding acquisition (equal), Resources (equal)
Search for more papers by this authorCorresponding Author
Chen Chen
Department of Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Correspondence:
Jianfei Huang ([email protected])
Chen Chen ([email protected])
Contribution: Funding acquisition (equal), Investigation (equal), Methodology (equal), Project administration (equal), Writing - review & editing (equal)
Search for more papers by this authorCorresponding Author
Jianfei Huang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Correspondence:
Jianfei Huang ([email protected])
Chen Chen ([email protected])
Contribution: Conceptualization (lead), Data curation (lead), Funding acquisition (lead), Investigation (lead)
Search for more papers by this authorXiaojing Zhang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Contribution: Conceptualization (equal), Data curation (equal), Formal analysis (lead), Funding acquisition (equal), Methodology (lead), Software (lead), Writing - original draft (lead)
Search for more papers by this authorSutian Jiang
Department of Pathology, Lishui People's Hospital, Lishui, Zhejiang, China
Contribution: Conceptualization (equal), Data curation (equal), Methodology (equal), Software (equal), Writing - original draft (equal)
Search for more papers by this authorHang Yin
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Contribution: Formal analysis (equal), Investigation (equal), Methodology (equal)
Search for more papers by this authorHui Zhang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Contribution: Methodology (equal), Resources (equal), Software (equal)
Search for more papers by this authorLei Yang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Contribution: Formal analysis (equal), Software (equal), Software (equal), Validation (equal), Validation (equal)
Search for more papers by this authorPingping Sun
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Contribution: Conceptualization (equal), Investigation (equal)
Search for more papers by this authorXiaoling Kuai
Department of Gastroenterology, Nantong University Affiliated Hospital, Nantong, Jiangsu, China
Contribution: Funding acquisition (equal), Resources (equal)
Search for more papers by this authorCorresponding Author
Chen Chen
Department of Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Correspondence:
Jianfei Huang ([email protected])
Chen Chen ([email protected])
Contribution: Funding acquisition (equal), Investigation (equal), Methodology (equal), Project administration (equal), Writing - review & editing (equal)
Search for more papers by this authorCorresponding Author
Jianfei Huang
Clinical and Translational Research Center, Affiliated Hospital of Nantong University and Medical School of Nantong University, Nantong, Jiangsu, China
Department of Clinical Biobank and Institute of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Correspondence:
Jianfei Huang ([email protected])
Chen Chen ([email protected])
Contribution: Conceptualization (lead), Data curation (lead), Funding acquisition (lead), Investigation (lead)
Search for more papers by this authorFunding: This work was supported by National Natural Science Foundation of China, 82303008, 82303877, 81902334, 82073025. Jiangsu Province Capability Improvement Project through Science, Technology, and Education, ZDXK202234. Jiangsu Provincial Research Hospital, YJXYY202204. The China Postdoctoral Science Foundation Fund, 2023M731819. The Science and Technology Project of Nantong, Jiangsu, China, MS2023049.
Xiaojing Zhang and Sutian Jiang contributed equally to this work.
ABSTRACT
Background
Gastric cancer (GC) remains a prevalent and lethal malignancy worldwide, underscoring the urgent need to identify novel therapeutic targets and elucidate the tumor microenvironment (TME) to enhance clinical outcomes.
Methods
IL36RN mRNA expression in GC tissues was analyzed using The Cancer Genome Atlas (TCGA) dataset. Bioinformatics approaches, cellular models, and clinical tissue microarrays were employed to investigate the functional role of IL36RN, its interactions within the TME, and its prognostic significance.
Results
IL36RN expression was markedly upregulated in GC tissues and associated with unfavorable survival outcomes. Functional assays demonstrated that IL36RN silencing suppressed GC cell proliferation and invasion. Elevated IL36RN expression correlated with enhanced CD8+ T cell infiltration in the TME and served as an independent prognostic indicator in GC.
Conclusions
IL36RN represents a potential prognostic biomarker and therapeutic target in GC, offering novel avenues for precision oncology and immunotherapeutic intervention.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The datasets generated during and/or analyzed during the current study are not publicly available due [The data involves private patient information.] but are available from the corresponding author on reasonable request.
References
- 1F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.
- 2G. Kroemer, T. A. Chan, A. M. M. Eggermont, and L. Galluzzi, “Immunosurveillance in Clinical Cancer Management,” CA: A Cancer Journal for Clinicians 74, no. 2 (2024): 187–202.
- 3Z. X. Liao, S. H. Hsu, S. C. Tang, I. Kempson, P. C. Yang, and S. J. Tseng, “Potential Targeting of the Tumor Microenvironment to Improve Cancer Virotherapy,” Pharmacology & Therapeutics 250 (2023): 108521.
- 4N. Niknafs, A. Balan, C. Cherry, et al., “Persistent Mutation Burden Drives Sustained Anti-Tumor Immune Responses,” Nature Medicine 29, no. 2 (2023): 440–449.
- 5J. Park, P. C. Hsueh, Z. Li, and P. C. Ho, “Microenvironment-Driven Metabolic Adaptations Guiding CD8(+) T Cell Anti-Tumor Immunity,” Immunity 56, no. 1 (2023): 32–42.
- 6S. M. Giannitelli, V. Peluzzi, S. Raniolo, et al., “On-Chip Recapitulation of the Tumor Microenvironment: A Decade of Progress,” Biomaterials 306 (2024): 122482.
- 7N. Zacharakis, H. Chinnasamy, M. Black, et al., “Immune Recognition of Somatic Mutations Leading to Complete Durable Regression in Metastatic Breast Cancer,” Nature Medicine 24, no. 6 (2018): 724–730.
- 8R. Bai, Z. Lv, D. Xu, and J. Cui, “Predictive Biomarkers for Cancer Immunotherapy With Immune Checkpoint Inhibitors,” Biomarker Research 8 (2020): 34.
- 9J. A. Carter, P. Gilbo, and G. S. Atwal, “IMPRES Does Not Reproducibly Predict Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma,” Nature Medicine 25, no. 12 (2019): 1833–1835.
- 10E. Tran, P. F. Robbins, and S. A. Rosenberg, “'Final Common Pathway' of Human Cancer Immunotherapy: Targeting Random Somatic Mutations,” Nature Immunology 18, no. 3 (2017): 255–262.
- 11L. A. Walsh and D. F. Quail, “Decoding the Tumor Microenvironment With Spatial Technologies,” Nature Immunology 24, no. 12 (2023): 1982–1993.
- 12M. Binnewies, E. W. Roberts, K. Kersten, et al., “Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy,” Nature Medicine 24, no. 5 (2018): 541–550.
- 13J. X. Lin and W. J. Leonard, “Fine-Tuning Cytokine Signals,” Annual Review of Immunology 37 (2019): 295–324.
- 14W. E. Paul, “Pleiotropy and Redundancy: T Cell-Derived Lymphokines in the Immune Response,” Cell 57, no. 4 (1989): 521–524.
- 15D. J. Propper and F. R. Balkwill, “Harnessing Cytokines and Chemokines for Cancer Therapy,” Nature Reviews. Clinical Oncology 19, no. 4 (2022): 237–253.
- 16M. Elias, S. Zhao, H. T. le, et al., “IL-36 in Chronic Inflammation and Fibrosis - Bridging the Gap?,” Journal of Clinical Investigation 131, no. 2 (2021): e144336.
- 17M. F. Neurath, “IL-36 in Chronic Inflammation and Cancer,” Cytokine & Growth Factor Reviews 55 (2020): 70–79.
- 18J. E. Towne, B. R. Renshaw, J. Douangpanya, et al., “Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36alpha, IL-36beta, and IL-36gamma) or Antagonist (IL-36Ra) Activity,” Journal of Biological Chemistry 286, no. 49 (2011): 42594–42602.
- 19S. Hussain, D. M. Berki, S. E. Choon, et al., “IL36RN Mutations Define a Severe Autoinflammatory Phenotype of Generalized Pustular Psoriasis,” Journal of Allergy and Clinical Immunology 135, no. 4 (2015): 1067–1070.
- 20A. Mullard, “FDA Approves First Anti-IL-36 Receptor Antibody for Rare Skin Disease,” Nature Reviews. Drug Discovery 21, no. 11 (2022): 786.
- 21S. Jiang, X. Ding, Q. Wu, T. Cheng, M. Xu, and J. Huang, “Identifying Immune Cells-Related Phenotype to Predict Immunotherapy and Clinical Outcome in Gastric Cancer,” Frontiers in Immunology 13 (2022): 980986.
- 22A. Onoufriadis, M. A. Simpson, A. E. Pink, et al., “Mutations in IL36RN/IL1F5 Are Associated With the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis,” American Journal of Human Genetics 89, no. 3 (2011): 432–437.
- 23M. S. Gresnigt and F. L. van de Veerdonk, “Biology of IL-36 Cytokines and Their Role in Disease,” Seminars in Immunology 25, no. 6 (2013): 458–465.
- 24E. Melton and H. Qiu, “Interleukin-36 Cytokine/Receptor Signaling: A New Target for Tissue Fibrosis,” International Journal of Molecular Sciences 21, no. 18 (2020): 6458.
- 25D. Queen, C. Ediriweera, and L. Liu, “Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development,” Frontiers in Cell and Development Biology 7 (2019): 317.
- 26N. Tsurutani, P. Mittal, M. C. St. Rose, et al., “Costimulation Endows Immunotherapeutic CD8 T Cells With IL-36 Responsiveness During Aerobic Glycolysis,” Journal of Immunology 196, no. 1 (2016): 124–134.
- 27X. Wang, X. Zhao, C. Feng, et al., “IL-36gamma Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses,” Cancer Cell 28, no. 3 (2015): 296–306.
- 28F. Ahmad, M. A. Alam, A. W. Ansari, et al., “Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases,” Journal of Investigative Dermatology 144, no. 2 (2024): 206–224.
- 29R. Debets, J. C. Timans, B. Homey, et al., “Two Novel IL-1 Family Members, IL-1 Delta and IL-1 Epsilon, Function as an Antagonist and Agonist of NF-Kappa B Activation Through the Orphan IL-1 Receptor-Related Protein 2,” Journal of Immunology 167, no. 3 (2001): 1440–1446.
- 30J. Keller, J. R. O' Siorain, T. M. Kündig, and M. Mellett, “Molecular Aspects of Interleukin-36 Cytokine Activation and Regulation,” Biochemical Society Transactions 52, no. 4 (2024): 1591–1604.
- 31J. Velcicky, G. Cremosnik, C. Scheufler, et al., “Discovery of Selective Low Molecular Weight Interleukin-36 Receptor Antagonists by Encoded Library Technologies,” Nature Communications 16, no. 1 (2025): 1669.
- 32P. Wang, W. Yang, H. Guo, et al., “IL-36gamma and IL-36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress-Induced Cell Death,” Advanced Science (Weinheim) 8, no. 19 (2021): e2101501.
- 33C. Gabay and J. E. Towne, “Regulation and Function of Interleukin-36 Cytokines in Homeostasis and Pathological Conditions,” Journal of Leukocyte Biology 97, no. 4 (2015): 645–652.
- 34M. A. Boutet, G. Bart, M. Penhoat, et al., “Distinct Expression of Interleukin (IL)-36alpha, Beta and Gamma, Their Antagonist IL-36Ra and IL-38 in Psoriasis, Rheumatoid Arthritis and Crohn's Disease,” Clinical and Experimental Immunology 184, no. 2 (2016): 159–173.
- 35T. Efferth and F. Oesch, “The Immunosuppressive Activity of Artemisinin-Type Drugs Towards Inflammatory and Autoimmune Diseases,” Medicinal Research Reviews 41, no. 6 (2021): 3023–3061.
- 36M. Farooq, H. Nakai, A. Fujimoto, et al., “Mutation Analysis of the IL36RN Gene in 14 Japanese Patients With Generalized Pustular Psoriasis,” Human Mutation 34, no. 1 (2013): 176–183.
- 37M. F. Sanmamed and L. Chen, “A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization,” Cell 176, no. 3 (2019): 677.
